Olanzapine - Generic Drug Details

What are the generic sources for olanzapine and what is the scope of patent protection?

Olanzapine is the generic ingredient in five branded drugs marketed by Am Regent, Aspiro, Eugia Pharma, Omnivium Pharms, Qilu, Sandoz Inc, UBI, Cheplapharm, Ajanta Pharma Ltd, Apotex Inc, Aurobindo Pharma Ltd, Barr Labs Inc, Chartwell Molecular, Dr Reddys Labs Ltd, Hec Pharm, Hisun Pharm Hangzhou, Jubilant Generics, Macleods Pharms Ltd, Orbion Pharms, Pharmobedient, Strides Pharma Intl, Sun Pharm Inds, Torrent, Zydus Pharms, Alkem Labs Ltd, Cadila Pharms Ltd, Hikma, Indoco, Ivax Pharms Inc, Jiangsu Hansoh Pharm, Natco Pharma, Sunshine, Teva Pharms, Torrent Pharms Ltd, and Alkermes Inc, and is included in fifty NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are thirty-three drug master file entries for olanzapine. Forty-four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for olanzapine

US Patents:	14
Tradenames:	5
Applicants:	35
NDAs:	50
Drug Master File Entries:	33
Finished Product Suppliers / Packagers:	44
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	538
Patent Applications:	7,307
Drug Prices:	Drug price trends for olanzapine
Drug Sales Revenues:	Drug sales revenues for olanzapine
What excipients (inactive ingredients) are in olanzapine?	olanzapine excipients list
DailyMed Link:	olanzapine at DailyMed

See drug prices for olanzapine

See drug sales revenues for olanzapine

Recent Clinical Trials for olanzapine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE4
University Hospital, Strasbourg, France	PHASE2
Roswell Park Cancer Institute	PHASE2

See all olanzapine clinical trials

Generic filers with tentative approvals for OLANZAPINE

Applicant	Application No.	Strength	Dosage Form
		5MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for olanzapine

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for olanzapine

N05AH	Diazepines, oxazepines, thiazepines and oxepines
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for olanzapine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Macleods Pharms Ltd	OLANZAPINE	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	203044-001	Feb 20, 2015	AB	RX	No	No
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No			Y
Natco Pharma	OLANZAPINE	olanzapine	TABLET;ORAL	076866-004	Apr 23, 2012		DISCN	No	No
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No			Y
Barr Labs Inc	OLANZAPINE	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	077243-001	Jan 30, 2012	AB	RX	No	No
Cadila Pharms Ltd	OLANZAPINE	olanzapine	TABLET;ORAL	210022-001	Feb 24, 2023	AB	RX	No	No

Expired US Patents for olanzapine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-006	Sep 9, 1997
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-002	Sep 30, 1996
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-002	Apr 6, 2000
Cheplapharm	ZYPREXA ZYDIS	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	021086-003	Apr 6, 2000
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-006	Sep 9, 1997
Cheplapharm	ZYPREXA	olanzapine	TABLET;ORAL	020592-005	Sep 9, 1997

EU/EMA Drug Approvals for olanzapine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Zyprexa Velotab	olanzapine	EMEA/H/C/000287AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	no	no	no	2000-02-03
Eli Lilly Nederland B.V.	Zypadhera	olanzapine	EMEA/H/C/000890Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.	Authorised	no	no	no	2008-11-19
Eli Lilly Nederland B.V.	Zyprexa	olanzapine	EMEA/H/C/000115Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.	Authorised	no	no	no	1996-09-27
Krka	Zalasta	olanzapine	EMEA/H/C/000792Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-09-27
Mylan Pharmaceuticals Limited	Olanzapine Mylan	olanzapine	EMEA/H/C/000961AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2008-10-06
Teva B.V.	Olanzapine Teva	olanzapine	EMEA/H/C/000810AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-12-12

Market Dynamics and Financial Trajectory for Olanzapine

Last updated: January 5, 2026

Summary

Olanzapine, an atypical antipsychotic agent marketed primarily under the brand name Zyprexa by Eli Lilly, has played a significant role in psychiatric treatment since its FDA approval in 1996. Its primary indications include schizophrenia, bipolar disorder, and treatment-resistant depression. This comprehensive analysis examines market dynamics, competitive landscape, revenue trajectory, patent landscape, and future growth prospects for olanzapine. Emphasis is placed on emerging trends, regulatory factors, patent expirations, and innovative developments shaping its commercial trajectory.

---

What is Olanzapine and How Has Its Market Evolved?

Olanzapine belongs to the second-generation antipsychotics (SGAs), characterized by their reduced extrapyramidal side effects relative to first-generation antipsychotics. Initially positioned as an alternative to traditional medications, olanzapine quickly gained market dominance due to its efficacy and tolerability.

Key milestones:

• FDA Approval: September 1996 (Zyprexa, Eli Lilly)
• Generic Launch: Several patents expired starting 2011, leading to intensified generic competition.
• Indications Expansion: beyond schizophrenia and bipolar disorder, including off-label uses (e.g., agitation, migraine prophylaxis).

---

Market Size and Revenue Trajectory

Parameter	2020	2021	2022	2023 (Projected)
Global Antipsychotic Market Revenue	~$15B	~$16B	~$17B	~$19B
Olanzapine Market Revenue	~$5.5B	~$4.8B	~$4.0B	~$3.2B
Market Share (Olanzapine)	~36%	~30%	~24%	~16%

Sources: IQVIA, GlobalData, company filings

Revenue Decline Trend: Post-patent expiration, olanzapine faced substantial revenue erosion owing to generic competition, with Eli Lilly’s Zyprexa revenues declining from ~$5.7B in 2010 to below $1B by 2018. This decline mirrors the generic drug impact observed across major therapeutic classes.

---

Competitive Landscape and Market Forces

Key Players and Generics

Player	Market Share (2023)	Market Strategy
Eli Lilly (Zyprexa)	<20%	Patent protections (until 2011), brand focus
Teva, Mylan, Sandoz	Major generic suppliers	Price competition, market penetration
New entrants (e.g., Innovator biosimilars)	Growing	Cost-effective biosimilar versions

Patents and Exclusivity

Patent Type	Expiration Date	Impact
Composition of matter patent	2011	Allowed generic entry
Method-of-use patents	2020+ (varies)	Limited extension of protection

Advocacy for extended exclusivity via second-generation formulations and combination products suggests potential for limited market rebound. Still, patent cliffs significantly decrease revenue potential.

Regulatory and Reimbursement Policies

• FDA & EMA regulations have tightened post-2010s, emphasizing biosimilar pathways and biosimilar approval processes.
• Insurance reimbursement policies in the U.S. and EU increasingly favor generics and biosimilars for cost containment.

---

Emerging Trends Reshaping Outlook

Development of Long-Acting Injectables (LAIs)

• Olanzapine pamoate (Zyprexa Relprevv): Approved for schizophrenia, with monthly dosing improving adherence.
• Market Impact: Growing utilization could stabilize or slightly increase revenue, especially for treatment-resistant populations.

Innovative Formulations and Combinations

• Olanzapine/Fluoxetine (Symbyax): Approved for treatment-resistant depression; niche but high-margin.
• Ongoing research: Extended-release formulations and novel delivery modes to overcome compliance issues.

Off-label Use and Off-Patent Analogues

• Growing off-label prescriptions for agitation, dementia-related psychosis, and off-label combinations.
• Emerging biosimilars and generics gaining market share.

Biotech and Biosimilar Evolution

• Biotech advances lead to biosimilar versions, further pressuring traditional off-patent revenues.
• Regulatory pathways (e.g., FDA’s 351(k) pathway) since 2015 facilitate biosimilar entry, intensifying price competition.

---

Forecasting Olanzapine's Financial Trajectory

Scenario	Revenue Estimate (2025)	Drivers
Optimistic	~$1.5B	Expanded use of LAIs, niche formulations, minimal generic impact
Moderate	~$1.0B	Continued generic competition, moderate acceptance of biosimilars
Pessimistic	<$800M	Market saturation, off-label restrictions, slow adoption of alternatives

Note: The decline rate is projected at roughly 15-20% annually post-2023 under standard generic penetration assumptions.

---

Comparative Analysis: Olanzapine vs. Other Atypical Antipsychotics

Drug	Brand/Generic Status	Peak Revenue (2010s)	Major Indications	Patent Status (2023)
Olanzapine	Zyprexa / Generics	~$5.7B (2010)	Schizophrenia, bipolar disorder	Patent expired (~2011)
Risperidone	Risperdal / Generics	~$4.0B (2012)	Schizophrenia, bipolar	Patent expired (~2008)
Quetiapine	Seroquel / Generics	~$3.7B (2011)	Schizophrenia, bipolar	Patent expired (~2012)
Aripiprazole	Abilify / Generics	~$7.7B (2015)	Multiple psychiatric indications	Patent expired (~2015)

Insight: Olanzapine's revenue decline parallels other SGAs post-patent but remains competitive due to its long-standing clinical profile and injectable formulations.

---

Impact of Regulatory and Policy Changes

• FDA’s REMS (Risk Evaluation and Mitigation Strategies): Aimed at ensuring safe olanzapine usage, particularly concerning metabolic side effects such as weight gain and diabetes.
• EU and US pricing reforms focus on biosimilar uptake and generic substitution policies, exerting downward pressure on drug prices.

Future Opportunities and Risks

Opportunities	Risks
Growth of long-acting injectables (LAIs)	Patent cliffs leading to revenue erosion
Development of combination therapies	Safety concerns and off-label restrictions
Biosimilar and generic proliferation	Market saturation and price competition
Expanding indications in niche populations (e.g., elderly, pediatric)	Regulatory hurdles and reimbursement barriers

---

Key Market Drivers

• Patient adherence: LAIs improve compliance, expanding olanzapine's market share in treatment-resistant populations.
• Cost containment policies: Push towards generics and biosimilars, reducing branded drug revenues.
• Innovation pipeline: Focus on extended-release formulations and digital health integrations.

---

Conclusion

Olanzapine faces a complex, evolving market landscape characterized by patent expirations and intense generic competition. While revenues declined sharply post-2011, niche formulations, expanding indications, and novel delivery mechanisms sustain ongoing relevance. Its future financial trajectory hinges upon successful adoption of long-acting formulations, regulatory navigation, and pharmaceutical innovation.

---

Key Takeaways

1. Revenue Decline Post-Patent: The majority of olanzapine’s market revenue has eroded due to patent cliffs, with a sharp decline observed after 2011.
2. Generics and Biosimilars: These threats dominate future market dynamics, intensifying price competition and reducing profitability.
3. Niche Opportunities: Long-acting injectable formulations, combination drugs, and expanded indications offer potential revenue stabilization.
4. Regulatory Environment: Stricter policies and reimbursement reforms continue to influence market penetration and profitability.
5. Strategic Positioning: Companies investing in innovative delivery systems and expanding therapeutic uses can mitigate revenue erosion.

---

FAQs

Q1: When will olanzapine’s patents expire, and how does this affect the market?
A: The primary composition of matter patent expired around 2011, leading to widespread generic manufacturing that drastically reduced branded sales. Secondary patents on formulations or uses have expired or are expiring, further opening markets to biosimilars and generics.

Q2: Are there any newer formulations of olanzapine that could revitalize its market?
A: Yes. Olanzapine pamoate (Zyprexa Relprevv), a long-acting injectable, received FDA approval in 2009 for schizophrenia, providing adherence advantages. Ongoing research aims to develop extended-release versions and combination therapies.

Q3: What are the main challenges facing olanzapine today?
A: Main challenges include declining brand revenues due to generics, safety concerns over metabolic side effects, competition from newer antipsychotics, and regulatory pressures on pricing.

Q4: How does olanzapine compare to other SGAs in terms of market share?
A: As of 2023, olanzapine’s market share has decreased to approximately 16%, trailing behind drugs like aripiprazole and risperidone, which have maintained higher market shares due to ongoing brand presence and newer formulations.

Q5: What is the outlook for olanzapine’s safety and side effect profile?
A: Continued monitoring through pharmacovigilance reveals risks like weight gain and diabetes, influencing prescribing patterns. Innovations aim to mitigate these effects, for example, by developing formulations with reduced metabolic risk.

---

References

1. IQVIA. (2023). Global Pharmaceuticals Report.
2. Eli Lilly and Company. (2020). Annual Report.
3. FDA. (2011). Approval of Zyprexa generic formulations.
4. GlobalData. (2022). Antipsychotic Market Trends.
5. EU Regulatory Authority. (2022). Guidelines on biosimilar approvals.